报告接种 ChAdOx1 nCoV-19 冠状病毒疫苗（重组）的医护人员中的不良事件：一项横断面调查。
Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.
机构信息
Department of Nursing, National Institute of Nursing Education, Chandigarh, India.
Department of Anaesthesia, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
出版信息
Indian J Med Res. 2022 Jan;155(1):123-128. doi: 10.4103/ijmr.ijmr_1221_21.
BACKGROUND & OBJECTIVES: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals.
METHODS
This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it.
RESULTS
A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 ±11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs.
INTERPRETATION & CONCLUSIONS: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.
背景与目的
许多已经接种疫苗的人对腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）的安全性表示担忧。人们对疫苗的不良反应有许多顾虑和担忧。因此，本研究旨在确定 ChAdOx1 nCoV-19 冠状病毒疫苗（重组）在医护人员中的安全性概况。
方法
这是一项描述性的横断面调查。在获得机构伦理委员会的批准后，我们选择了过去两周内接种过疫苗的 1500 名医护人员。我们为他们提供了一份关于 COVID-19 疫苗接种后不良反应（AEFIs）的在线调查表格，该表格使用谷歌表格开发，并附有知情同意书。
结果
共有 1036 人参与了这项研究。参与者的平均年龄和中位数（四分位间距）分别为 37.7 ±11.25 岁和 35（29-46）岁。其中，52.1%为女性，29.3%为医生，33.4%为护士，9.5%为辅助医疗人员。46%的参与者在接种部位出现了一种或多种轻微的 AEFIs，如疼痛、压痛、红肿等。疲劳（31.75%）、全身不适（28.57%）、肌肉疼痛（23.16%）和发热（21.71%）是最常见的全身 AEFIs，其次是头痛（20.07%）、头晕（10.03%）和关节疼痛（15.25%）。他们大多数人在接种第一剂疫苗后 24 小时内出现这些 AEFIs。约 42%的参与者为了治疗 AEFIs，服用了口服解热镇痛药/止痛药。
解释与结论
ChAdOx1 nCoV-19 冠状病毒疫苗与轻度局部和全身 AEFIs 相关，这些不良反应在第一剂后比第二剂更为常见。这些不良反应可以通过口服非处方药物来处理，不需要住院治疗。
Zotero 插件